An Observational Post-authorisation Safety Specialist Cohort Event Monitoring Study (SCEM) to Monitor the Safety and Utilization of Rivaroxaban (Xarelto Rm) for the Prevention of Stroke in Patients with AF, Treatment of DVT and PE, and the Prevention of Recurrent DVT and PE in the Secondary Care Hospital Setting in England and Wales

Trial Profile

An Observational Post-authorisation Safety Specialist Cohort Event Monitoring Study (SCEM) to Monitor the Safety and Utilization of Rivaroxaban (Xarelto Rm) for the Prevention of Stroke in Patients with AF, Treatment of DVT and PE, and the Prevention of Recurrent DVT and PE in the Secondary Care Hospital Setting in England and Wales

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 28 Aug 2016

At a glance

  • Drugs Rivaroxaban (Primary) ; Anticoagulants
  • Indications Deep vein thrombosis; Pulmonary embolism; Stroke
  • Focus Adverse reactions
  • Acronyms ROSE
  • Most Recent Events

    • 19 Feb 2016 Planned End Date changed from 31 Dec 2016 to 31 Dec 2015
    • 28 Jan 2016 Planned End Date changed from 18 Feb 2017 to 31 Dec 2016 as reported by United Kingdom Clinical Research Network.
    • 28 Jan 2016 Accrual to date is 139% according to the United Kingdom Clinical Research Network record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top